Nuestro blog

In three short years, decentralized clinical trials (DCTs) have turned skeptics into believers. Trial sponsors who were once hesitant are now embracing the DCT model—and for good reason. Today’s DCTs are addressing longstanding industry challenges, expanding access to patients and clinicians, increasing diversity, accelerating cohort recruitment, and improving retention.

When it comes to decentralized clinical trials (DCTs), the pharmaceutical industry finds itself at a crossroads.

For patients with rare, incurable, or life-threatening diseases, clinical trials can offer new hope. Cancer patients, specifically, are often highly motivated to participate in research, particularly when they have an advanced or treatment-resistant form of cancer. Find out how decentralized clinical trials reach patients in the comfort of their homes.

While there's broad agreement on the gap between white and non-white participation in clinical trial enrollment, the number of non-white patients enrolled in clinical trials for general population studies is still quite low.‍ But why?

Digital instruments such as sensors and wearables are transforming the industry’s definition of accuracy in three measures: volume, practicality, and precision.

One of the keys to optimizing ePRO is deploying artificial intelligence (AI) to support human participants and clinical teams.

The unique challenges associated with women’s health, and women as a cohort, make clinical research in this sector especially difficult. DCTs are helping to tackle the obstacles.

eConsent can mitigate these shortcomings by providing flexibility and engagement that empower patients with information and sponsors with data integrity.

Diversity in clinical trials is a scientific imperative, a moral and ethical necessity—and a longstanding challenge in clinical research. DCTs are evolving the industry status quo.

Combining the ease of ePRO with expert rating—patient convenience with the objectivity of experts—facilitates more accurate data collection.